{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T07:44:35Z","timestamp":1794037475185,"version":"4.8.0"},"reference-count":150,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100021821","name":"Oncode Institute","doi-asserted-by":"publisher","award":["NGFOP2201"],"award-info":[{"award-number":["NGFOP2201"]}],"id":[{"id":"10.13039\/501100021821","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.xcrm.2025.102412","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T19:26:20Z","timestamp":1760556380000},"page":"102412","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Dendritic cell immunotherapy advances for solid tumors: Vaccination and modulation"],"prefix":"10.1016","volume":"6","author":[{"given":"Georgia","family":"Clayton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa C.","family":"Toffoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja D.","family":"de Gruijl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette","family":"van Kooyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2025.102412_bib1","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2025.102412_bib2","doi-asserted-by":"crossref","DOI":"10.1126\/science.abf9419","article-title":"Tertiary lymphoid structures in cancer","volume":"375","author":"Schumacher","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2025.102412_bib3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.smim.2009.05.010","article-title":"The role of CD40 and CD154\/CD40L in dendritic cells","volume":"21","author":"Ma","year":"2009","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.xcrm.2025.102412_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.794776","article-title":"Discordance in STING-Induced Activation and Cell Death Between Mouse and Human Dendritic Cell Populations","volume":"13","author":"Pang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.102412_bib5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3389\/fimmu.2014.00159","article-title":"Cross-Talks between Natural Killer Cells and Distinct Subsets of Dendritic Cells","volume":"5","author":"Ferlazzo","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.102412_bib6","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: Indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2025.102412_bib7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2567.2011.03457.x","article-title":"Complexity of dendritic cell subsets and their function in the host immune system","volume":"133","author":"Kushwah","year":"2011","journal-title":"Immunology"},{"key":"10.1016\/j.xcrm.2025.102412_bib8","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/ni.1615","article-title":"The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues","volume":"9","author":"Waskow","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2025.102412_bib9","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood.V95.11.3489","article-title":"Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells","volume":"95","author":"McKenna","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102412_bib10","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood-2011-11-370130","article-title":"Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy","volume":"119","author":"van de Laar","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102412_bib11","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/PAP.0b013e3181bb6bc2","article-title":"Plasmacytoid dendritic cells: physiologic roles and pathologic states","volume":"16","author":"Jegalian","year":"2009","journal-title":"Adv. Anat. Pathol."},{"key":"10.1016\/j.xcrm.2025.102412_bib12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/imm.12888","article-title":"Human dendritic cell subsets: an update","volume":"154","author":"Collin","year":"2018","journal-title":"Immunology"},{"key":"10.1016\/j.xcrm.2025.102412_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000588","article-title":"Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy","volume":"8","author":"Schetters","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.102412_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000832","article-title":"Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy","volume":"9","author":"Prokopi","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.102412_bib15","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200264","article-title":"Tumor-infiltrating dendritic cell states are conserved across solid human cancers","volume":"218","author":"Gerhard","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.xcrm.2025.102412_bib16","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.immuni.2020.06.002","article-title":"Transcriptional and Functional Analysis of CD1c(+) Human Dendritic Cells Identifies a CD163(+) Subset Priming CD8(+)CD103(+) T Cells","volume":"53","author":"Bourdely","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2025.102412_bib17","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/eji.202149632","article-title":"Human dendritic cell subsets: An updated view of their ontogeny and functional specialization","volume":"52","author":"Segura","year":"2022","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.xcrm.2025.102412_bib18","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.xcrm.2025.102412_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2025.102412_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.733800","article-title":"Control of Dendritic Cell Function Within the Tumour Microenvironment","volume":"13","author":"Gupta","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.102412_bib21","first-page":"1860","article-title":"Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines","volume":"63","author":"Kobie","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102412_bib22","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.clim.2011.11.011","article-title":"IL-10-generated tolerogenic dendritic cells are optimal for functional regulatory T cell induction--a comparative study of human clinical-applicable DC","volume":"142","author":"Boks","year":"2012","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.xcrm.2025.102412_bib23","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1080\/21645515.2018.1431598","article-title":"Inhibition of IL-10 and TGF-beta receptors on dendritic cells enhances activation of effector T-cells to kill cholangiocarcinoma cells","volume":"14","author":"Thepmalee","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.xcrm.2025.102412_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1213629","article-title":"Impaired function of dendritic cells within the tumor microenvironment","volume":"14","author":"Xiao","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.102412_bib25","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1111\/cas.14091","article-title":"Vascular endothelial growth factor (VEGF) impairs the motility and immune function of human mature dendritic cells through the VEGF receptor 2-RhoA-cofilin1 pathway","volume":"110","author":"Long","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.xcrm.2025.102412_bib26","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-021-01102-5","article-title":"The relationship between expression of PD-L1 and HIF-1alpha in glioma cells under hypoxia","volume":"14","author":"Ding","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2025.102412_bib27","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/430394","article-title":"The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance","volume":"2011","author":"Janikashvili","year":"2011","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.xcrm.2025.102412_bib28","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/s41467-021-21550-4","article-title":"Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9","volume":"12","author":"Rodriguez","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102412_bib29","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.3389\/fimmu.2018.02807","article-title":"Modulation of Immune Tolerance via Siglec-Sialic Acid Interactions","volume":"9","author":"Lubbers","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.102412_bib30","doi-asserted-by":"crossref","first-page":"41053","DOI":"10.18632\/oncotarget.9419","article-title":"Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses","volume":"7","author":"Silva","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2025.102412_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abm9409","article-title":"Human dendritic cells in cancer","volume":"7","author":"Kvedaraite","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.xcrm.2025.102412_bib32","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.immuni.2019.08.008","article-title":"Single-Cell Analysis of Human Mononuclear Phagocytes Reveals Subset-Defining Markers and Identifies Circulating Inflammatory Dendritic Cells","volume":"51","author":"Dutertre","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2025.102412_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007554","article-title":"Allogeneic NK cells induce monocyte-to-dendritic cell conversion, control tumor growth, and trigger a pro-inflammatory shift in patient-derived cultures of primary and metastatic colorectal cancer","volume":"11","author":"Toffoli","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.102412_bib34","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.immuni.2017.11.001","article-title":"High-Dimensional Phenotypic Mapping of Human Dendritic Cells Reveals Interindividual Variation and Tissue Specialization","volume":"47","author":"Alcantara-Hernandez","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2025.102412_bib35","doi-asserted-by":"crossref","DOI":"10.1126\/science.aah4573","article-title":"Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors","volume":"356","author":"Villani","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2025.102412_bib36","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.4049\/jimmunol.168.9.4333","article-title":"Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation","volume":"168","author":"Sombroek","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.xcrm.2025.102412_bib37","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.4049\/jimmunol.1100889","article-title":"M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells","volume":"187","author":"Heusinkveld","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.xcrm.2025.102412_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2326-5","article-title":"Author Correction: A conserved dendritic-cell regulatory program limits antitumour immunity","volume":"582","author":"Maier","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102412_bib39","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s10585-023-10257-z","article-title":"Antigen presenting cells in cancer immunity and mediation of immune checkpoint blockade","volume":"41","author":"Wang","year":"2024","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.xcrm.2025.102412_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117580","article-title":"Dendritic cell therapy in cancer treatment; the state-of-the-art","volume":"254","author":"Sadeghzadeh","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.xcrm.2025.102412_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113365","article-title":"A comprehensive review of immune checkpoint inhibitors for cancer treatment","volume":"143","author":"Arafat Hossain","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.xcrm.2025.102412_bib42","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s40265-022-01723-1","article-title":"Nivolumab Plus Relatlimab: First Approval","volume":"82","author":"Paik","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.xcrm.2025.102412_bib43","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2025.102412_bib44","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1158\/2159-8290.CD-15-0510","article-title":"Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells","volume":"6","author":"Sanchez-Paulete","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102412_bib45","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41586-019-1836-5","article-title":"An intra-tumoral niche maintains and differentiates stem-like CD8 T cells","volume":"576","author":"Jansen","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102412_bib46","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","article-title":"Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy","volume":"31","author":"Spranger","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102412_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2021.101481","article-title":"The role of dendritic cells in cancer and anti-tumor immunity","volume":"52","author":"Marciscano","year":"2021","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.xcrm.2025.102412_bib48","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102412_bib49","article-title":"Direct Delivery of Antigens to Dendritic Cells via Antibodies Specific for Endocytic Receptors as a Promising Strategy for Future Therapies","volume":"4","author":"Lehmann","year":"2016","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.xcrm.2025.102412_bib50","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41392-020-00448-5","article-title":"Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer","volume":"6","author":"Ding","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.xcrm.2025.102412_bib51","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008068","article-title":"Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205","volume":"6","author":"Dhodapkar","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2025.102412_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102845","article-title":"Safety and immunogenicity of CD40.HIVRI.Env, a dendritic cell-based HIV vaccine, in healthy HIV-uninfected adults: a first-in-human randomized, placebo-controlled, dose-escalation study (ANRS VRI06)","volume":"77","author":"Levy","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.xcrm.2025.102412_bib53","doi-asserted-by":"crossref","first-page":"6432","DOI":"10.1039\/D2NR07071E","article-title":"Biomimetic nanoparticles for DC vaccination: a versatile approach to boost cancer immunotherapy","volume":"15","author":"Meng","year":"2023","journal-title":"Nanoscale"},{"key":"10.1016\/j.xcrm.2025.102412_bib54","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41571-024-00902-1","article-title":"Cancer mRNA vaccines: clinical advances and future opportunities","volume":"21","author":"Sayour","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102412_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122703","article-title":"Dendritic cell-targeting polymer nanoparticle-based immunotherapy for cancer: A review","volume":"635","author":"Hu","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.xcrm.2025.102412_bib56","doi-asserted-by":"crossref","first-page":"907","DOI":"10.2217\/fon-2017-0531","article-title":"Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions","volume":"14","author":"Handy","year":"2018","journal-title":"Future Oncol."},{"key":"10.1016\/j.xcrm.2025.102412_bib57","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00262-022-03272-8","article-title":"Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trial","volume":"72","author":"Adams","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.xcrm.2025.102412_bib58","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006665","article-title":"Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III\/IV melanoma: a prespecified 36-month analysis","volume":"11","author":"Carpenter","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.102412_bib59","doi-asserted-by":"crossref","first-page":"6126","DOI":"10.1245\/s10434-021-09709-1","article-title":"A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III\/IV Melanoma: A Primary Analysis","volume":"28","author":"Vreeland","year":"2021","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.xcrm.2025.102412_bib60","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1038\/s41467-024-48073-y","article-title":"TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial","volume":"15","author":"Everson","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102412_bib61","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007070","article-title":"Adjuvant dendritic cell-based immunotherapy after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with malignant peritoneal mesothelioma: a phase II clinical trial","volume":"11","author":"Dietz","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.102412_bib62","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S1470-2045(24)00191-8","volume":"25","author":"Aerts","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2025.102412_bib63","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1158\/1078-0432.CCR-22-1927","article-title":"A Therapeutic Antigen-Presenting Cell-Targeting DNA Vaccine VB10.16 in HPV16-Positive High-Grade Cervical Intraepithelial Neoplasia: Results from a Phase I\/IIa Trial","volume":"28","author":"Hillemanns","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102412_bib64","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1038\/s41467-020-18962-z","article-title":"Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients","volume":"11","author":"Block","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102412_bib65","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1158\/1078-0432.CCR-20-1082","article-title":"Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma","volume":"26","author":"Batich","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102412_bib66","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","article-title":"Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial","volume":"9","author":"Liau","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.xcrm.2025.102412_bib67","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009765","article-title":"Dendritic cells pulsed with multifunctional Wilms' tumor 1 (WT1) peptides combined with multiagent chemotherapy modulate the tumor microenvironment and enable conversion surgery in pancreatic cancer","volume":"12","author":"Koido","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.102412_bib68","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102412_bib69","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003190","article-title":"Safety and efficacy of dendritic cell-based immunotherapy DCVAC\/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial","volume":"10","author":"Rob","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.102412_bib70","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1158\/1078-0432.CCR-21-4413","article-title":"An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors","volume":"28","author":"Fucikova","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102412_bib71","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003675","article-title":"Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma","volume":"9","author":"Storkus","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.102412_bib72","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1792058","article-title":"Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination","volume":"9","author":"Lovgren","year":"2020","journal-title":"OncoImmunology"},{"key":"10.1016\/j.xcrm.2025.102412_bib73","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002449","article-title":"Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma","volume":"9","author":"Saberian","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.102412_bib74","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/s41591-022-01771-w","article-title":"Author Correction: A phase 1\/2 trial of an immune-modulatory vaccine against IDO\/PD-L1 in combination with nivolumab in metastatic melanoma","volume":"28","author":"Kjeldsen","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2025.102412_bib75","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1038\/s41467-024-45358-0","article-title":"Adjuvant dendritic cell therapy in stage IIIB\/C melanoma: the MIND-DC randomized phase III trial","volume":"15","author":"Bol","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102412_bib76","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1001\/jamaoncol.2021.7298","article-title":"Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial","volume":"8","author":"Vogelzang","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.xcrm.2025.102412_bib77","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1758004","article-title":"Dexamethasone premedication suppresses vaccine-induced immune responses against cancer","volume":"9","author":"Vormehr","year":"2020","journal-title":"OncoImmunology"},{"key":"10.1016\/j.xcrm.2025.102412_bib78","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.annonc.2024.08.169","article-title":"161P Fibroblast activation protein (FAP)-CD40 (RO7300490) mediates intratumoral DC maturation and modulation of the tumor microenvironment","volume":"35","author":"Melero","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2025.102412_bib79","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-21-1047","article-title":"Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer","volume":"27","author":"Byrne","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102412_bib80","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(24)00263-8","article-title":"Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b\/2 study","volume":"25","author":"Van Laethem","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2025.102412_bib81","doi-asserted-by":"crossref","first-page":"viii712","DOI":"10.1093\/annonc\/mdy424.015","article-title":"LBA15 - Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas","volume":"29","author":"Harrington","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2025.102412_bib82","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1158\/1078-0432.CCR-22-2235","article-title":"Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced\/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study","volume":"29","author":"Meric-Bernstam","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102412_bib83","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1158\/1078-0432.CCR-23-0118","article-title":"Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies","volume":"29","author":"Luke","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102412_bib84","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1158\/1078-0432.CCR-23-2808","article-title":"Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors","volume":"30","author":"Tolcher","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102412_bib85","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1038\/s43018-020-00143-y","article-title":"Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets","volume":"1","author":"Bhardwaj","year":"2020","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.xcrm.2025.102412_bib86","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1038\/s41467-023-39196-9","article-title":"A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma","volume":"14","author":"Heumann","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102412_bib87","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41467-025-56619-x","article-title":"The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial","volume":"16","author":"Mora","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102412_bib88","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s43018-024-00879-x","article-title":"Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial)","volume":"6","author":"Ressler","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.xcrm.2025.102412_bib89","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006270","article-title":"Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial","volume":"11","author":"Chesney","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.102412_bib90","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.22.00343","article-title":"Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma","volume":"41","author":"Chesney","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102412_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114120","article-title":"Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti-PD-1 therapy: MASTERKEY-115","volume":"207","author":"Robert","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.xcrm.2025.102412_bib92","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1158\/1078-0432.CCR-20-1170","article-title":"Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study","volume":"26","author":"Harrington","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102412_bib93","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae203","article-title":"Phase Ib\/II trial of talimogene laherparepvec alone and with pembrolizumab in advanced solid tumors with liver metastases and hepatocellular carcinoma","volume":"30","author":"Hecht","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.xcrm.2025.102412_bib94","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102412_bib95","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1001\/jamaoncol.2023.4015","article-title":"Toll-Like Receptor 4 Agonist Injection With Concurrent Radiotherapy in Patients With Metastatic Soft Tissue Sarcoma: A Phase 1 Nonrandomized Controlled Trial","volume":"9","author":"Seo","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.xcrm.2025.102412_bib96","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1200\/JCO.20.03452","article-title":"Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1","volume":"40","author":"Chawla","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102412_bib97","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1530262","article-title":"Pilot clinical trial of neoadjuvant toll-like receptor 7 agonist (Imiquimod) immunotherapy in early-stage oral squamous cell carcinoma","volume":"16","author":"Yoon","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.102412_bib98","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011173","article-title":"Topical TLR7 agonist and radiotherapy in patients with metastatic breast cancer","volume":"13","author":"Adams","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.102412_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103643","article-title":"A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies","volume":"9","author":"Curigliano","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.xcrm.2025.102412_bib100","first-page":"A199.1","article-title":"324 BDB001, a Toll-Like receptor 7 and 8 (TLR7\/8) agonist, can be safely administered intravenously and shows clinical responses in advanced solid tumors","volume":"8","author":"Patel","year":"2020","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"10.1016\/j.xcrm.2025.102412_bib101","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1158\/2159-8290.CD-21-0425","article-title":"Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma","volume":"11","author":"Ribas","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102412_bib102","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1158\/2159-8290.CD-20-1546","article-title":"Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma","volume":"11","author":"Haymaker","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102412_bib103","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/j.ccell.2024.10.007","article-title":"Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial","volume":"42","author":"Davar","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102412_bib104","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1158\/1078-0432.CCR-21-1411","article-title":"Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naive Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial","volume":"28","author":"Cohen","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102412_bib105","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006136","article-title":"Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors","volume":"11","author":"Lemech","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.102412_bib106","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/30845","article-title":"Immunology. Licence to kill","volume":"393","author":"Lanzavecchia","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102412_bib107","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41423-021-00734-4","article-title":"CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies","volume":"19","author":"Bullock","year":"2022","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.xcrm.2025.102412_bib108","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3389\/fimmu.2019.01325","article-title":"Costimulatory Molecules and Immune Checkpoints Are Differentially Expressed on Different Subsets of Dendritic Cells","volume":"10","author":"Carenza","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.102412_bib109","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adj5097","article-title":"Cancer immunotherapy via synergistic coactivation of myeloid receptors CD40 and Dectin-1","volume":"8","author":"Wattenberg","year":"2023","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.xcrm.2025.102412_bib110","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1126\/science.1198443","article-title":"CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans","volume":"331","author":"Beatty","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2025.102412_bib111","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1200\/JCO.2006.08.3311","article-title":"Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody","volume":"25","author":"Vonderheide","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102412_bib112","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10637-022-01319-2","article-title":"A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors","volume":"41","author":"Moreno","year":"2023","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.xcrm.2025.102412_bib113","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cytogfr.2023.11.002","article-title":"Harnessing the potential of CD40 agonism in cancer therapy","volume":"75","author":"Zhou","year":"2024","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.xcrm.2025.102412_bib114","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s43018-022-00329-6","article-title":"Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting","volume":"3","author":"Salomon","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.xcrm.2025.102412_bib115","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1158\/0008-5472.CAN-22-0094","article-title":"Efficacy of CD40 Agonists Is Mediated by Distinct cDC Subsets and Subverted by Suppressive Macrophages","volume":"82","author":"Murgaski","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102412_bib116","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10081822","article-title":"How Chemotherapy Affects the Tumor Immune Microenvironment: A Narrative Review","volume":"10","author":"Merlano","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.xcrm.2025.102412_bib117","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102412_bib118","unstructured":"BioStock (2024). Alligator prepares for phase III with CD40 agonist. https:\/\/www.biostock.se\/en\/2024\/02\/alligator-prepares-for-phase-iii-with-cd40-agonist\/."},{"key":"10.1016\/j.xcrm.2025.102412_bib119","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41698-021-00197-w","article-title":"Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients","volume":"5","author":"Boucher","year":"2021","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.xcrm.2025.102412_bib120","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/1078-0432.CCR-23-0475","article-title":"A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy","volume":"30","author":"Weiss","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102412_bib121","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nature10429","article-title":"STING is a direct innate immune sensor of cyclic di-GMP","volume":"478","author":"Burdette","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102412_bib122","article-title":"Clinical applications of STING agonists in cancer immunotherapy: current progress and future prospects","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.102412_bib123","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112695","article-title":"STING Agonists as Cancer Therapeutics","volume":"13","author":"Amouzegar","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xcrm.2025.102412_bib124","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.omtn.2018.11.003","article-title":"An Analysis of the Expression and Association with Immune Cell Infiltration of the cGAS\/STING Pathway in Pan-Cancer","volume":"14","author":"An","year":"2019","journal-title":"Mol Ther-Nucl Acids"},{"key":"10.1016\/j.xcrm.2025.102412_bib125","doi-asserted-by":"crossref","first-page":"5461","DOI":"10.1038\/s41467-023-41164-2","article-title":"Optogenetic engineering of STING signaling allows remote immunomodulation to enhance cancer immunotherapy","volume":"14","author":"Dou","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102412_bib126","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/s42003-021-02004-5","article-title":"ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance","volume":"4","author":"Jang","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.xcrm.2025.102412_bib127","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1038\/s41467-020-16602-0","article-title":"Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity","volume":"11","author":"Leventhal","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102412_bib128","doi-asserted-by":"crossref","DOI":"10.2217\/mmt-2020-0011","article-title":"An update on GM-CSF and its potential role in melanoma management","volume":"7","author":"O Dillman","year":"2020","journal-title":"Melanoma Manag."},{"key":"10.1016\/j.xcrm.2025.102412_bib129","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1038\/s12276-024-01353-5","article-title":"Cytokine-overexpressing dendritic cells for cancer immunotherapy","volume":"56","author":"Han","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.xcrm.2025.102412_bib130","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00262-008-0536-z","article-title":"Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines","volume":"57","author":"de Gruijl","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.xcrm.2025.102412_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102536","article-title":"Genetic adjuvants: A paradigm shift in vaccine development and immune modulation","volume":"36","author":"Spunde","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.xcrm.2025.102412_bib132","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071525","article-title":"The Flt3L\/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy","volume":"13","author":"Cueto","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xcrm.2025.102412_bib133","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.901277","article-title":"GM-CSF: A Double-Edged Sword in Cancer Immunotherapy","volume":"13","author":"Kumar","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.102412_bib134","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/cas.13027","article-title":"Oncolytic virus therapy: A new era of cancer treatment at dawn","volume":"107","author":"Fukuhara","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.xcrm.2025.102412_bib135","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2025.102412_bib136","doi-asserted-by":"crossref","first-page":"6506","DOI":"10.3390\/v7122953","article-title":"Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy","volume":"7","author":"Kim","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.xcrm.2025.102412_bib137","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/1568009618666171129221503","article-title":"Oncorine, the World First Oncolytic Virus Medicine and its Update in China","volume":"18","author":"Liang","year":"2018","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.xcrm.2025.102412_bib138","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1634\/theoncologist.2019-0438","article-title":"Intratumoral Immunotherapy-Update 2019","volume":"25","author":"Hamid","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.xcrm.2025.102412_bib139","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47\u0394 for residual or recurrent glioblastoma: a phase 2 trial","volume":"28","author":"Todo","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2025.102412_bib140","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ccell.2025.03.010","article-title":"The discrete charm of oncolytic viruses: Toward the finish line","volume":"43","author":"Lowenstein","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102412_bib141","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1177\/10781552241312920","article-title":"Talimogene laherparepvec (T-VEC) as a treatment for melanoma: A systematic review","volume":"31","author":"Alla","year":"2025","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.xcrm.2025.102412_bib142","article-title":"Efficacy and safety of oncolytic virus combined with chemotherapy or immune checkpoint inhibitors in solid tumor patients: A meta-analysis","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.xcrm.2025.102412_bib143","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1200\/OP.23.00675","article-title":"Systemic Therapy for Melanoma: ASCO Guideline Update Q and A","volume":"20","author":"Sondak","year":"2024","journal-title":"JCO Oncol. Pract."},{"key":"10.1016\/j.xcrm.2025.102412_bib144","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41698-023-00364-1","article-title":"Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer","volume":"7","author":"Rolfo","year":"2023","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.xcrm.2025.102412_bib145","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2180237","article-title":"Trial watch: Toll-like receptor ligands in cancer therapy","volume":"12","author":"Le Naour","year":"2023","journal-title":"OncoImmunology"},{"key":"10.1016\/j.xcrm.2025.102412_bib146","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2297453","article-title":"Toll-like receptor agonists as cancer vaccine adjuvants","volume":"20","author":"Jeon","year":"2024","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.xcrm.2025.102412_bib147","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1172\/JCI61345","article-title":"Plasmacytoid dendritic cells lead the charge against tumors","volume":"122","author":"Jimenez-Baranda","year":"2012","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2025.102412_bib148","doi-asserted-by":"crossref","first-page":"4566","DOI":"10.1158\/1078-0432.CCR-21-0263","article-title":"A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non-small Cell Lung Cancer","volume":"27","author":"Garon","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102412_bib149","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1158\/1078-0432.CCR-11-1716","article-title":"Clinical effects of adjuvant active specific immunotherapy differ between patients with microsatellite-stable and microsatellite-instable colon cancer","volume":"18","author":"de Weger","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102412_bib150","first-page":"12","article-title":"Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state","volume":"63","author":"De Vries","year":"2003","journal-title":"Cancer Res."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125004859?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125004859?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:54:52Z","timestamp":1785902092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379125004859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":150,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2666379125004859"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102412","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dendritic cell immunotherapy advances for solid tumors: Vaccination and modulation","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102412","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102412"}}